Ruthenium(II) complexes with hydroxypyridinecarboxylates: Screening potential metallodrugs against Mycobacterium tuberculosis

Barbosa, Marília Imaculada Frazão; Corrêa, Rodrigo S.; Pozzi, Lucas V.; Lopes, Érica de Oliveira; Pavan, Fernando Rogério; Leite, Clarice Q. F.; Ellena, Javier; Machado, Sérgio de Paula; Poelhsitz, Gustavo Von; Batista, Alzir A.

doi:10.1016/j.poly.2014.08.057

Cited by 24 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Structure of the most promising ruthenium complexes in medicinal chemistry Selected Ru(II)-Bisdiphenylphosphine metal complexes with significant antimycobacterial properties prepared in our group[14][15][16][17][18] …”

mentioning

confidence: 99%

Ru(II)/clotrimazole/diphenylphosphine/bipyridine complexes: Interaction with DNA, BSA and biological potential against tumor cell lines and Mycobacterium tuberculosis

Colina‐Vegas

Dutra

Villarreal

et al. 2016

Journal of Inorganic Biochemistry

Self Cite

View full text Add to dashboard Cite

Three ruthenium complexes [RuCl(CTZ)(bipy)(P-P)]PF [P-P=1,2-bis(diphenylphosphino)ethane (dppe-1), 1,4-bis(diphenylphosphino)butane (dppb-2) and 1,1'-bis(diphenylphosphino)ferrocene (dppf-3), bipy=2,2'-bipiridine and clotrimazole (CTZ) 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole] were synthesized. These complexes were characterized by a combination of elemental analysis, molar conductivity, infrared and UV-vis spectroscopy, H,C{H} and P{H} nuclear magnetic resonance techniques, cyclic voltammetry and mass spectroscopy. Bovine serum albumin binding constants, which were in the range of 1.30-36.00×10M, and thermodynamic parameters suggest spontaneous interactions with this protein by electrostatic forces due to the positive charge of the complexes. DNA interactions studied by spectroscopic titration, viscosity measurements, gel electrophoresis, circular dichroism, ethidium bromide displacement and reactions with guanosine and guanosine monophosphate indicated the DNA binding affinity primarily through non-covalent interactions. All complexes 1-3 were tested against the human carcinoma cell lines MCF-7 (breast), A549 (lung) and DU-145 (prostate) presenting promising IC values, between 0.50 and 14.00μM, in some cases lower than the IC for the reference drug (cisplatin). The antimicrobial activity assays of the complexes provided evidence that they are potential agents against mycobacterial infections, specifically against Mycobacterium tuberculosis H37Rv.

show abstract

mentioning

confidence: 99%

Ru(II)/clotrimazole/diphenylphosphine/bipyridine complexes: Interaction with DNA, BSA and biological potential against tumor cell lines and Mycobacterium tuberculosis

Colina‐Vegas

Dutra

Villarreal

et al. 2016

Journal of Inorganic Biochemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…antimycobacterial activity and a completely lack of cytotoxicity activity, indicating a good selectivity index. [38] Xu The silver and cadmium complexes were effective against the root-knot nematode M.…”

Section: Scheme-2: Structure Of Mixed Ligand Complex Involving Nicotimentioning

confidence: 99%

A Review on Coordination Behaviour and Bioactivity of Metal Complexes of Nicotinic Acid and Its Derivatives

Bhojak¹

2017

WJPPS

View full text Add to dashboard Cite

Nicotinic acid and its derivatives are potent biological chelating ligands as most of them have N, S, and O donor atoms that can act as coordinating sites for metal ion coordination. Like these ligands, their metal complexes also have many important biological activities such as antibacterial, antifungal, antiviral, antitumor, anti-inflammatory etc.and are also found to be pharmacologically and physiologically active.Many such metal complexes of nicotinic acid and its derivatives have supramolecular association i.e. 3D framework structure via hydrogen or covalent bonds. The most relevant papers recently published are reviewed with an attempt to focus the bioactivity and structure of such metal complexes along with some related applications.

show abstract

“…Furthermore, one of the most known and promising in this class, RAPTA-C, ruthenium-arene complex containing the phosphine 1,3,5-Triaza-7phosphaadamantane (PTA), is currently on phase I clinical trial for cancer treatment [33]. Additionally, other phosphine-containing ruthenium complexes are also active against cancer cells, bacteria and Mycobacterium tuberculosis (MTb) [34][35][36][37][38][39][40].…”

Section: Introductionmentioning

confidence: 99%

“…In the past few years several ruthenium complexes have been investigated regarding anti-MTb activity, including one containing isoniazid as ligand [38,40,42,43]. Some diphosphine-containing ruthenium complexes, such as cis-[Ru(pic)(dppe) 2 ]PF 6 (pic = 2-picolinic acid; dppe = 1,2-bis(diphenylphosphino)ethane), presented MIC 90 comparable to first and second line drugs [40].…”

Section: Introductionmentioning

confidence: 99%

Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents

Silva

Silva²,

Pavan³

et al. 2017

Journal of Inorganic Biochemistry

Self Cite

View full text Add to dashboard Cite

Several ruthenium complexes have been investigated regarding anti-Mycobacterium tuberculosis (anti-MTb) activity, with some diphosphine-containing ruthenium complexes comparable to first and second line drugs. However, to the best of our knowledge, there is no PNP-containing ruthenium complexes applied as metallodrugs. Thus, this study focused on the synthesis, characterization and anti-MTb activity of a new series of coordination compounds with general formula [RuCl(η-p-cymene)(PNP)]X (R=CHPy (Py=pyridine)-[1a], CHPh (Ph=phenyl)-[1b], Ph-[1c] and p-tol (p-tol=p-tolyl)-[1d]; X=PF or BF). The complexes were fully characterized by NMR (H, P{H}), vibrational spectroscopy (FTIR), ESI-MS, molar conductance, elemental analysis and X-ray diffraction studies. The molecular structures of [1a]PF, [1c]BF and [1d]PF were determined and confirm the spectroscopic and ESI-MS data. The complexes were used in anti-MTb trials, and the preliminary results are presented. The complexes are promising anti-MTb agents with MIC (Minimum Inhibitory Concentration of compounds required to inhibit the growth of 90% of MTb) values comparable with the Ethambutol, the reference drug used in this work, and complex [1a]BF presented the highest selectivity index.

show abstract

Ruthenium(II) complexes with hydroxypyridinecarboxylates: Screening potential metallodrugs against Mycobacterium tuberculosis

Cited by 24 publications

References 37 publications

Ru(II)/clotrimazole/diphenylphosphine/bipyridine complexes: Interaction with DNA, BSA and biological potential against tumor cell lines and Mycobacterium tuberculosis

Ru(II)/clotrimazole/diphenylphosphine/bipyridine complexes: Interaction with DNA, BSA and biological potential against tumor cell lines and Mycobacterium tuberculosis

A Review on Coordination Behaviour and Bioactivity of Metal Complexes of Nicotinic Acid and Its Derivatives

Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents

Contact Info

Product

Resources

About